CD274 and oculopharyngeal muscular dystrophy: In recent clinical trials evaluating PD-1- and PD-L1 targeting monoclonal antibodies (pembrolizumab and avelumab) patients with OPMD at high-risk of oral cancer development based on LOH status have been enrolled (NCT02882282 and NCT04504552), but the results are still awaited.